Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species

European Journal of Pharmacology

Volumn 560, Issue 2-3, 2007, Pages 216-224

  Rowland, Steven E ^a   Clark, Patsy ^a   Gordon, Robert ^a   Mullen, Anne K ^a   Guay, Jocelyne ^a   Dufresne, Lynn ^a   Brideau, Christine ^a   Cote, Bernard ^a   Ducharme, Yves ^a   Mancini, Joseph ^a   Chan, Chi chung ^a   Audoly, Laurent ^a   Xu, Daigen ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

(Guinea pig); (Mouse); (Rabbit); (Rat); Air pouch; Inflammation; Prostaglandin; Pyresis

Indexed keywords

3 (3,4 DIFLUOROPHENYL) 4 [4 (METHYLSULFONYL)PHENYL] 2(5H) FURANONE; CARRAGEENAN; CYCLOOXYGENASE 2 INHIBITOR; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FREUND ADJUVANT; PROSTAGLANDIN E2; RECOMBINANT INTERLEUKIN 1BETA; THROMBOXANE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GUINEA PIG; INFLAMMATION; KNEE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RABBIT; RAT; SYNOVIUM; TREATMENT OUTCOME;

ANALGESICS, NON-NARCOTIC; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FURANS; GUINEA PIGS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; STOMACH;

EID: 33847615631     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.01.008     Document Type: Article

References (41)

1. Black S.C., Brideau C., Cirino M., Belley M., Bosquet J., Chan C.C., and Rodger I.W. Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs. J. Cardiovasc. Pharmacol. 32 (1998) 686-694
2. Brideau C., Kargman S., Liu S., Dallob A.L., Ehrich E.W., Rodger I.W., and Chan C.C. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm. Res. 45 (1996) 68-74
3. Brideau C., Van Staden C., and Chan C.C. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am. J. Vet. Res. 62 (2001) 1755-1760
4. Chan C.C., Boyce S., Brideau C., Ford-Hutchinson A.W., Gordon R., Guay D., Hill R.G., Li C.S., Mancini J., and Penneton M. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 274 (1995) 1531-1537
5. Chan C.C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson A.W., Forrest M.J., Gauthier J.Y., Gordon R., Gresser M., Guay J., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O'Neill G.P., Ouellet M., Patrick D., Percival M.D., Perrier H., Prasit P., and Rodger I. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J. Pharmacol. Exp. Ther. 290 (1999) 551-560
6. Cheng Z.J., Finckenberg P., Louhelainen M., Merasto S., Tikkanen I., Vapaatalo H., and Mervaala E.M. Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27). Eur. J. Pharmacol. 461 (2003) 159-169
7. Chu A.J., Chou T.H., and Chen B.D. Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. Front. Biosci. 9 (2004) 2697-2713
8. Cryer B., and Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am. J. Med. 104 (1998) 413-421
9. Davidson J., Abul H.T., Milton A.S., and Rotondo D. Cytokines and cytokine inducers stimulate prostaglandin E2 entry into the brain. Pflugers Arch. 442 (2001) 526-533
10. Engblom D., Saha S., Engstrom L., Westman M., Audoly L.P., Jakobsson P.J., and Blomqvist A. Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis. Nat. Neurosci. 6 (2003) 1137-1138
11. Fleischmann R., Stern R., and Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 4 (2004) 1333-1344
12. Goldenberg M.M. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin. Ther. 21 (1999) 1497-1513
13. Hemler M., and Lands W.E. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J. Biol. Chem. 251 (1976) 5575-5579
14. Hetu P.O., and Riendeau D. Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. Biochem. J. 391 (2005) 561-566
15. Hoffmann C. COX-2 in brain and spinal cord implications for therapeutic use. Curr. Med. Chem. 7 (2000) 1113-1120
16. Huntjens D.R., Danhof M., and Della Pasqua O.E. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) 44 (2005) 846-859
17. Huntjens D.R., Spalding D.J., Danhof M., and Della Pasqua O.E. Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. Br. J. Pharmacol. 148 (2006) 396-404
18. Komers R., Tian W., Lindsley J.N., Oyama T.T., Cohen D.M., and Anderson S. Effects of cyclooxygenase-2 (COX-2) inhibition on plasma and renal renin in diabetes. J. Lab. Clin. Med. 140 (2002) 351-357
19. Kontny E., Rudnicka W., Kowalczewski J., Marcinkiewicz J., and Maslinski W. Selective inhibition of cyclooxygenase 2-generated prostaglandin E2 synthesis in rheumatoid arthritis synoviocytes by taurine chloramine. Arthritis Rheum. 48 (2003) 1551-1555
20. Kowanko I.C., Gordon T.P., Rozenbilds M.A., Brooks P.M., and Roberts-Thomson P.J. The subcutaneous air pouch model of synovium and the inflammatory response to heat aggregated gammaglobulin. Agents Actions 18 (1986) 421-428
21. Langenbach R., Morham S.G., Tiano H.F., Loftin C.D., Ghanayem B.I., Chulada P.C., Mahler J.F., Davis B.J., and Lee C.A. Disruption of the mouse cyclooxygenase 1 gene. Characteristics of the mutant and areas of future study. Adv. Exp. Med. Biol. 407 (1997) 87-92
22. Li S., Wang Y., Matsumura K., Ballou L.R., Morham S.G., and Blatteis C.M. The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2(-/-), but not in cyclooxygenase-1(-/-) mice. Brain Res. 825 (1999) 86-94
23. Lugarini F., Hrupka B.J., Schwartz G.J., Plata-Salaman C.R., and Langhans W. A role for cyclooxygenase-2 in lipopolysaccharide-induced anorexia in rats. Am. J. Physiol., Regul. Integr. Comp. Physiol. 283 (2002) R862-R868
24. Malmstrom K., Sapre A., Couglin H., Agrawal N.G., Mazenko R.S., and Fricke Jr. J.R. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin. Ther. 26 (2004) 667-679
25. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G., Isakson P.C., and Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3228-3232
26. Meagher E.A. Cardiovascular and renovascular implications of COX-2 inhibition. Curr. Pharm. Des. 10 (2004) 603-611
27. Miyamoto T., Ogino N., Yamamoto S., and Hayaishi O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J. Biol. Chem. 251 (1976) 2629-2636
28. Myers L.K., Kang A.H., Postlethwaite A.E., Rosloniec E.F., Morham S.G., Shlopov B.V., Goorha S., and Ballou L.R. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum. 43 (2000) 2687-2693
29. O'Banion M.K., Winn V.D., and Young D.A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 4888-4892
30. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., and Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
31. Oshima M., Murai N., Kargman S., Arguello M., Luk P., Kwong E., Taketo M.M., and Evans J.F. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61 (2001) 1733-1740
32. Patrignani P., Panara M.R., Greco A., Fusco O., Natoli C., Iacobelli S., Cipollone F., Ganci A., Creminon C., and Maclouf J. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 271 (1994) 1705-1712
33. Prasit P., Wang Z., Brideau C., Chan C.C., Charleson S., Cromlish W., Ethier D., Evans J.F., Ford-Hutchinson A.W., Gauthier J.Y., Gordon R., Guay J., Gresser M., Kargman S., Kennedy B., Leblanc Y., Leger S., Mancini J., O'Neill G.P., Ouellet M., Percival M.D., Perrier H., Riendeau D., Rodger I., and Zamboni R. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg. Med. Chem. Lett. 9 (1999) 1773-1778
34. Riendeau D., Percival M.D., Brideau C., Charleson S., Dube D., Ethier D., Falgueyret J.P., Friesen R.W., Gordon R., Greig G., Guay J., Mancini J., Ouellet M., Wong E., Xu L., Boyce S., Visco D., Girard Y., Prasit P., Zamboni R., Rodger I.W., Gresser M., Ford-Hutchinson A.W., Young R.N., and Chan C.C. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296 (2001) 558-566
35. Roth J., Hubschle T., Pehl U., Ross G., and Gerstberger R. Influence of systemic treatment with cyclooxygenase inhibitors on lipopolysaccharide-induced fever and circulating levels of cytokines and cortisol in guinea-pigs. Pflugers Arch. 443 (2002) 411-417
36. Rott D., Zhu J., Burnett M.S., Zhou Y.F., Zalles-Ganley A., Ogunmakinwa J., and Epstein S.E. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J. Am. Coll. Cardiol. 41 (2003) 1812-1819
37. Smith C.J., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., Talley J.J., Masferrer J.L., Seibert K., and Isakson P.C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13313-13318
38. Steiner A.A., Li S., Llanos Q., and Blatteis C.M. Differential inhibition by nimesulide of the early and late phases of intravenous-and intracerebroventricular-LPS-induced fever in guinea pigs. Neuroimmunomodulation 9 (2001) 263-275
39. Tavares E., Minano F.J., Maldonado R., and Dascombe M.J. Endotoxin fever in granulocytopenic rats: evidence that brain cyclooxygenase-2 is more important than circulating prostaglandin E2. J Leukoc Biol (2006)
40. Xie W.L., Chipman J.G., Robertson D.L., Erikson R.L., and Simmons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 2692-2696
41. Yamagata K., Matsumura K., Inoue W., Shiraki T., Suzuki K., Yasuda S., Sugiura H., Cao C., Watanabe Y., and Kobayashi S. Coexpression of microsomal-type prostaglandin E synthase with cyclooxygenase-2 in brain endothelial cells of rats during endotoxin-induced fever. J. Neurosci. 21 (2001) 2669-2677